« Return to News | R&D Trends | Drug Sponsors

Quintiles collaborates with PGT

Tuesday, May 17, 2011 11:32 AM

Quintiles has partnered with Population Genetics Technologies (PGT), a U.K.-based company that specializes in large-scale, lower-cost genomic analyses, according to PharmaTimes.

Quintiles’ view of its non-exclusive commercial collaboration with PGT is about bringing “genomic testing into mainstream drug development in order to produce safer, more effective medicines.”

The two companies will seek opportunities to apply large-scale genomic analyses in testing clinical hypotheses and correlating biomarkers of disease prognosis with drug responsiveness.

Quintiles’ global presence and PGT’s technology combined “can bring the benefits of large-scale sequencing and analysis to virtually all biopharmaceutical companies,” says M. King Jolly, senior vice president of Quintiles Innovation.

Other benefits that Jolly notes are improving success rates in clinical trials, reducing the volume of trial enrollment needed to achieve statistical significance and cutting the costs and/or time to bring a product to market.


Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.